Visual acuity after (at least) 2 years follow up in patients with uveitis treated with anti-TNF-α
| Patient | Total TNF infusions | VA before start | VA after at least 2 years follow up | Fundus lesions | Medications |
|---|---|---|---|---|---|
| 1 | 11 | RE: 20/30 | RE: 20/20 | Macular hole/fibrosis LE | Infliximab 200 mg iv, prednisone 1 mg/day, prednisone after 3 months ↓ to 10 mg/day |
| LE: LP+ | LE: CF | ||||
| 2 | 4 | RE: 20/50 | RE: 20/30 | Ischaemic optic atrophy, RE>LE | Infliximab 200 mg iv, cyclosporine 200 mg/day |
| LE: LP+ | LE: LP+ | ||||
| 3 | 7 | RE: 20/60 | RE: 20/80 | Optic atrophy, RE>LE | Infliximab 200 mg iv, MTX 3×/week |
| LE: 20/30 | LE: 20/40 | ||||
| 4 | 1 | RE: CF | RE: 20/200 | Macular fibrosis LE | Infliximab 200 mg iv |
| LE: 20/30 | LE: 20/30 | ||||
| 5 | 4 | RE: 20/200 | RE: 20/200 | Infliximab 200 mg iv, prednisone 15 mg/day, cyclosporine 300 mg/day | |
| 6 | 2 | RE: CF | RE: CF | CRVO; oedema posterior pole RE | Infliximab 200 mg iv, prednisone 20 mg/day, MTX 12.5 mg/week |
| A | 12 | RE: 20/150 | RE: 20/40 | Macular scarring RE+LE | Infliximab 200 mg iv, prednisone 10 mg/day, ledertrexate 1×/week |
| LE: 20/200 | LE: 20/100 | ||||
| B | 5 | RE: 20/40 | RE: 20/40 | Infliximab 200 mg iv, prednisone 10 mg/48 hours | |
| LE: CF | LE: CF | ||||
| C | 5 | RE: 20/50 | RE: 20/30 | Macular scarring RE | Infliximab 200 mg iv, prednisone 10 mg/day, cyclosporin 100 mg/day |
| LE: LP+ | LE: LP− | ||||
| D | 2 | RE: 20/400 | RE: CF | Fibrosis; disc swelling RE | Infliximab 200 mg iv, cyclosporin 100 mg/day, prednisone15 mg/day |
| LE: 20/120 | LE: 20/120 | ||||
| E | 4 | RE: 20/200 | RE: 20/100 | Disc swelling RE+LE | Infliximab 200 mg iv |
| LE: 20/200 | LE: 20/100 | ||||
| F | 3 | RE: 20/40 | RE: 20/40 | Macular oedema LE | Infliximab 200 mg iv, MTX 15 mg/week, with cyclosporin/MTX |
| LE: 20/60 | LE: 20/50 | STOP: dermatitis | |||
| G | 1 | RE: 20/120 | RE: 20/200 | STOP: rash | |
| LE: CF | LE: CF | Stable for 3 years: VA: RES 0.4–0.1, when progression: infliximab 200 mg iv |